Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
ONL Therapeutics
company
About
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2011
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptor cell.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$5.25M
ONL Therapeutics has raised a total of
$5.25M
in funding over 2 rounds. Their latest funding was raised on
May 17, 2017 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 17, 2017 | Series A | $4.25M | 1 | — | — | Detail |
| Mar 21, 2017 | Grant | $1M | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
ONL Therapeutics is funded by 2 investors.
National Institutes of Health
and Hestia Investments
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
